umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy
Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research (TWINCORE), Hannover, Germany. (Gisa Gerold)
2017 (English)In: Journal of Immunology Research, ISSN 2314-8861, E-ISSN 2314-7156, article id 7232361Article in journal (Refereed) Published
Abstract [en]

The human interferon (IFN) response is a key innate immune mechanism to fight virus infection. IFNs are host-encoded secreted proteins, which induce IFN-stimulated genes (ISGs) with antiviral properties. Among the three classes of IFNs, type III IFNs, also called IFN lambdas (IFNLs), are an essential component of the innate immune response to hepatitis C virus (HCV). In particular, human polymorphisms in IFNL gene loci correlate with hepatitis C disease progression and with treatment response. To date, the underlying mechanisms remain mostly elusive; however it seems clear that viral infection of the liver induces IFNL responses. As IFNL receptors show a more restricted tissue expression than receptors for other classes of IFNs, IFNL treatment has reduced side effects compared to the classical type I IFN treatment. In HCV therapy, however, IFNL will likely not play an important role as highly effective direct acting antivirals (DAA) exist. Here, we will review our current knowledge on IFNL gene expression, protein properties, signaling, ISG induction, and its implications on HCV infection and treatment. Finally, we will discuss the lessons learnt from the HCV and IFNL field for virus infections beyond hepatitis C.

Place, publisher, year, edition, pages
Hindawi Publishing Corporation, 2017. article id 7232361
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:umu:diva-148155DOI: 10.1155/2017/7232361ISI: 000394872000001PubMedID: 28255563OAI: oai:DiVA.org:umu-148155DiVA, id: diva2:1210789
Available from: 2018-05-29 Created: 2018-05-29 Last updated: 2018-10-16Bibliographically approved

Open Access in DiVA

fulltext(2654 kB)1 downloads
File information
File name FULLTEXT01.pdfFile size 2654 kBChecksum SHA-512
0f5c568e92fd2feec8b401e84cb41464d3e54a1a21c3cb95166f327e945e9d6c7b8458fc11f033a4b183244b4b285e777106608e17e0b9e8196cb9450c8c676a
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Gerold, Gisa

Search in DiVA

By author/editor
Gerold, Gisa
In the same journal
Journal of Immunology Research
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 1 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 7 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf